Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.85% | -1.04% | -3.68% | 8.96% | 10.44% |
| Total Depreciation and Amortization | -5.93% | -2.75% | 3.11% | 8.44% | 22.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.85% | -7.86% | -2.30% | -5.44% | 1.89% |
| Change in Net Operating Assets | -223.88% | -259.76% | -102.73% | -2.53% | 142.80% |
| Cash from Operations | -27.55% | -12.45% | -6.31% | 10.41% | 23.47% |
| Capital Expenditure | -18.52% | 18.91% | 41.91% | 50.17% | 78.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 489.17% | 2,298.05% | 289.77% | -80.93% | -92.88% |
| Cash from Investing | 787.11% | 1,411.72% | 280.58% | -83.81% | -94.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.10% | -78.10% | -87.97% | -87.75% | 0.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5,453.98% | 5,500.00% | -100.00% | -- | 1,009.75% |
| Cash from Financing | 19.70% | 19.80% | -88.06% | -86.78% | 2.68% |
| Foreign Exchange rate Adjustments | 583.49% | 277.60% | 115.03% | 444.79% | 25.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 193.50% | 819.94% | -32.97% | -178.78% | -44.79% |